Cancer最新文献

{"title":"Higher rates of long-term complications after prostate cancer treatment","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35761","DOIUrl":"https://doi.org/10.1002/cncr.35761","url":null,"abstract":"<p>Men with prostate cancer treated with prostatectomy and radiotherapy have significantly higher rates of long-term complications after accounting for age-related symptoms and disease, according to a cohort study published in <i>JAMA Oncology</i>.<span><sup>1</sup></span></p><p>Compared to people who did not undergo prostate cancer treatment, patients who underwent prostatectomy and those who underwent radiotherapy had 7.23- and 2.76-times greater risks, respectively, of developing urinary or sexual complications at 12 years.</p><p>Radiotherapy also was linked to a 3-fold increased risk of bladder cancer and a 100-fold increased risk of radiation cystitis and radiation proctitis.</p><p>The results are based on a novel approach to assessing the long-term risk of complications following prostate cancer treatment by comparing the risk in patients with prostate cancer who underwent treatment to the risk in a control population (untreated group) that included people without prostate cancer or with untreated prostate cancer. Data for all participants were obtained from two large prostate cancer prevention trials that allowed for a comparison of rates of age-dependent functional changes that increase with age (e.g., erectile dysfunction).</p><p>Among the 29,196 participants in the two trials, 3946 had prostate cancer: 655 underwent prostatectomy, and 1056 underwent radiotherapy.</p><p>Other findings included a higher rate of artificial urinary sphincter placement 12 years after prostatectomy (4.76 cases per 1000 years of follow-up) in comparison with untreated patients (who underwent no sphincter operations) and an increased rate of penile prosthesis implantation in participants who underwent prostatectomy or radiotherapy (4.40 and 1.50 times for each 1000 years of follow-up, respectively) in comparison with untreated participants (0.43 times for each 1000 years of follow-up).</p><p>According to the study authors led by Joseph M. Unger, PhD, a biostatistician at the SWOG Statistics and Data Management Center of the Fred Hutchinson Cancer Center, the findings “should be explicitly reflected in national cancer screening and treatment guidelines and be integral to shared decision-making with patients before initiation of prostate-specific antigen screening, biopsy, or prostate cancer treatment.” They note that quantitative information such as these findings on treatment-related risks of prostate cancer are not currently included in the guidelines of any national organization, and they recommend their inclusion to help to foster informed decision-making.</p><p>Walter M. Stadler, MD, Chief Clinical Officer for City of Hope, Chicago, says that the study re-emphasizes the need to discuss long-term urinary, sexual, and bowel toxicities with patients with prostate cancer before embarking on definitive local therapy.</p><p>“More importantly, these toxicities need to be balanced with known benefits of definitive local therapy, especially in patients for whom the ","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35761","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143638761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between cardiometabolic abnormalities and mortality in the Women’s Health Initiative: A comparison of associations among women with cancer to women without cancer","authors":"Sreejata Raychaudhuri MD,&nbsp;Eric McLaughlin MS,&nbsp;Michael L. Pennell PhD,&nbsp;Marcia Stefanick PhD,&nbsp;Kerryn Reding PhD,&nbsp;Alexi Vasbinder PhD,&nbsp;Richard K. Cheng MD,&nbsp;Ana Barac MD,&nbsp;Michael S. Simon MD, MPH","doi":"10.1002/cncr.35804","DOIUrl":"https://doi.org/10.1002/cncr.35804","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Prior studies of participants with breast and other obesity-associated cancers in the Women’s Health Initiative (WHI) showed worse mortality and cardiovascular disease (CVD) outcomes for individuals with a higher number of cardiometabolic risk factors at study entry. The purpose of this analysis is to compare the relationship between cardiometabolic abnormalities and mortality among women with and without cancer in the WHI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Women with one of five early-stage obesity-associated cancers (breast, colorectal, endometrial, ovarian, and non-Hodgkin lymphoma) and controls without any new or prior history of cancer were selected from the WHI-Life and Longevity after Cancer ancillary study. Cardiometabolic abnormalities included high waist circumference (≥88 cm), hypertension (&gt;130/85 mm Hg), and self-reported history of diabetes and/or elevated cholesterol. Multivariable Cox proportional hazards models (all-cause mortality) and Fine-Gray models (CVD and non-CVD mortality) were used to evaluate the association between cardiometabolic risk factors and survival outcomes for the cancer and noncancer cohorts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 7491 and 35,508 women were studied in the cancer and noncancer cohorts, respectively. Adjusted analyses showed that increased number of cardiometabolic abnormalities was associated with increased short-term risk of all-cause mortality, with the association being stronger among the noncancer “controls” compared to the cancer cohort (interaction <i>p</i> value = .02). Associations were similar between cancer cases and controls in competing risk models for CVD and non-CVD mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Preexisting cardiovascular abnormalities are an important predictor of adverse health outcomes among women with and without cancer in the WHI.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caring for caregivers in early-phase clinical oncology trials","authors":"Leah L. Thompson MD,&nbsp;Caterina S. Florissi BA,&nbsp;Debra Lundquist PhD, RN,&nbsp;Rachel B. Jimenez MD","doi":"10.1002/cncr.35805","DOIUrl":"https://doi.org/10.1002/cncr.35805","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The human oral microbiome and risk of colorectal cancer within three prospective cohort studies in the United States","authors":"Emily Vogtmann PhD, MPH,&nbsp;Yukiko Yano PhD, MPH,&nbsp;Semi Zouiouich PhD,&nbsp;Xing Hua PhD,&nbsp;Yunhu Wan PhD,&nbsp;Vaishnavi Purandare MS,&nbsp;Shilan Li PhD,&nbsp;Casey L. Dagnall BS,&nbsp;Kristine Jones BS,&nbsp;Belynda D. Hicks MS,&nbsp;Amy Hutchinson MS,&nbsp;J. Gregory Caporaso PhD,&nbsp;William Wheeler PhD,&nbsp;Wen-Yi Huang PhD,&nbsp;Neal D. Freedman PhD, MPH,&nbsp;Dale P. Sandler PhD, MPH,&nbsp;Laura E. Beane Freeman PhD,&nbsp;Linda M. Liao PhD,&nbsp;Mitchell H. Gail MD, PhD,&nbsp;Jianxin Shi PhD,&nbsp;Christian C. Abnet PhD, MPH,&nbsp;Rashmi Sinha PhD","doi":"10.1002/cncr.35802","DOIUrl":"https://doi.org/10.1002/cncr.35802","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Oral microbes detected in feces have been associated with colorectal cancer (CRC) in cross-sectional studies. This study investigated the prospective associations between the oral microbiome and incident CRC in the Agricultural Health Study (AHS), National Institutes of Health–AARP (NIH-AARP) Diet and Health Study, and Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Individuals with oral samples collected before incident CRC diagnoses were identified in the AHS (<i>N</i> = 331), NIH-AARP (<i>N</i> = 249), and PLCO (<i>N</i> = 446) and compared with referent subcohorts (<i>N</i> = 3431). The V4 region of the 16S ribosomal RNA gene was sequenced from oral wash DNA, and the data were processed with QIIME2. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall CRC and by anatomic subsite (i.e., proximal colon, distal colon, and rectum) were estimated with Cox proportional hazards models with adjustment for potential confounders by cohort and then meta-analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, no associations were found between microbial characteristics and CRC risk. However, associations were observed with alpha and beta diversity indices and individual genera in analyses stratified by anatomic subsite. For instance, the presence of <i>Olsenella</i> was strongly positively associated with distal colon cancer risk (HR, 2.16; 95% CI, 1.59–2.95), whereas the presence of <i>Prevotella 2</i> was positively associated with rectal cancer risk (HR, 1.68; 95% CI, 1.14–2.46).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This large study of the prospective association between the oral microbiome and CRC risk showed numerous site-specific associations, including multiple associations with distal colon and rectal cancer risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35802","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The missing data: A review of gender and sex disparities in research","authors":"Hannah C. Karpel MD, MS,&nbsp;Linda M. Zambrano Guevara MD,&nbsp;B. J. Rimel MD,&nbsp;Kari E. Hacker MD, PhD,&nbsp;Victoria Bae-Jump MD, PhD,&nbsp;Tara Castellano MD,&nbsp;John Curtin MD, MBA,&nbsp;Bhavana Pothuri MD, MS","doi":"10.1002/cncr.35769","DOIUrl":"https://doi.org/10.1002/cncr.35769","url":null,"abstract":"<p>This article highlights the gender data gaps in clinical trial inclusion and funding, with a particular focus on gynecologic oncology. Female patients have historically been excluded from clinical trials across all medical domains. Despite recent improvements, female patients remain underrepresented in key diseases, including several cancer types, despite experiencing increased burden of disease. Lack of representation is particularly stark for patients in racial, ethnic, and gender minoritized populations, including in gynecologic cancer trials. Furthermore, female health conditions receive disproportionately small amounts of funding relative to their disease burden. Despite their high lethality, gynecologic cancers, including ovarian, cervical, and uterine malignancies, rank among the lowest funded cancer sites from the National Cancer Institute. Likewise, there is significant bias against female investigators with regard to funding, publication, and academic advancement, which affects the prioritization of women’s health. In combination, gender disparities at multiple steps along the research pathway from investigator and disease funding to trial inclusion to publication and dissemination of research perpetuate a significant data gap in the diagnosis, treatment, and prevention of diseases affecting female patients, including gynecologic cancers. Strategies to improve this gender gap and prioritize women’s health funding include increasing female representation in clinical trials with a specific focus on inclusion of patients from historically marginalized backgrounds, considering disease burden–based funding policies, and prioritizing female academic leadership opportunities.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types","authors":"Eric V. Mastrolonardo MD,&nbsp;Pablo Llerena BS,&nbsp;Emma De Ravin MD,&nbsp;Kathryn Nunes BA,&nbsp;Praneet C. Kaki BS,&nbsp;Kelly M. Bridgham MD,&nbsp;Dev R. Amin MD,&nbsp;Daniel J. Campbell MD,&nbsp;Ramez Philips MD,&nbsp;Scott H. Koeneman PhD,&nbsp;David M. Cognetti MD,&nbsp;Adam J. Luginbuhl MD,&nbsp;Nicole L. Simone MD,&nbsp;Jennifer M. Johnson MD,&nbsp;Joseph M. Curry MD","doi":"10.1002/cncr.35799","DOIUrl":"https://doi.org/10.1002/cncr.35799","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction/Background</h3>\u0000 \u0000 <p>Obesity is a well-known risk factor for various cancers, yet emerging research demonstrates its association with improved survival outcomes in cancer treatment, labeled as “the obesity paradox.” Studies investigating the clinical benefits of obesity across various cancer types after immune checkpoint inhibition (ICI) are limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were queried from the TriNetX database to identify patients with solid tumor malignancies of various organ systems (pulmonary/intrathoracic, cutaneous, head and neck, gastrointestinal, breast, genitourinary) who received ICI between 2012 and 2024. Propensity score matching was used to match cohorts for demographics, medical comorbidities, and oncologic staging. Primary outcome was overall survival (OS) up to 5 years and compared between obese body mass index (BMI; &gt;30) and normal BMI (20–24.9) cohorts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After propensity score matching, there were a total of 18,434 patients, with 9217 patients in the obese BMI cohort and 9217 patients in the normal BMI cohort for all solid tumor malignancies. In the overall pan-cancer analysis, obese BMI was associated with significantly improved OS up to 5 years compared to the normal BMI cohort (hazard ratio [HR], 0.69 [0.66–0.72]). Subgroup analysis likewise demonstrated that obese BMI was associated with significantly improved OS up to 5 years for respiratory/intrathoracic (HR, 0.77 [0.72–0.83]), cutaneous (HR, 0.62 [0.63–0.78]), head and neck (HR, 0.67 [0.58–0.78]), gastrointestinal (HR, 0.67 [0.58–0.78]), breast (HR, 0.66 [0.55–0.79]), and genitourinary (HR, 0.57 [0.34–0.93]) malignancies (though not renal cell carcinoma specifically.)</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Obesity was associated with improved 5-year OS after treatment with ICI across various solid tumor malignancies in this electronic health record–based big data study. Further investigation is warranted to understand the mechanism of this association.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35799","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters","authors":"Vincent L. Cannataro PhD,&nbsp;Paige M. Bracci PhD, MPH,&nbsp;Jennie W. Taylor MD, MPH,&nbsp;Lucie McCoy MPH,&nbsp;Terri Rice MPH,&nbsp;Helen M. Hansen BA,&nbsp;Anne E. Heffernan MPH,&nbsp;Joseph Wiemels PhD,&nbsp;John Wiencke PhD,&nbsp;Margaret Wrensch PhD,&nbsp;Elizabeth B. Claus MD, PhD","doi":"10.1002/cncr.35732","DOIUrl":"https://doi.org/10.1002/cncr.35732","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Glioma is the most common malignant primary brain tumor and is associated with significant morbidity and mortality. Modifiable risk factors remain unidentified. New advances in exposure assessment, genomic analyses, and statistical techniques permit more accurate evaluation of glioma risk associated with exogenous occupational or environmental exposures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>By using whole-exome sequencing data from matched germline and glioma tumor samples, the authors compared tumor mutational signatures for 17 persons with glioma and a documented occupational history of firefighting with those of 18 persons with glioma without an occupational history of firefighting. All 35 individuals were participants in the University of California, San Francisco Adult Glioma Study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There was a positive correlation among firefighters between the median number of sample variants attributable to single-base substitution signature 42, a single-base substitution mutational signature associated with haloalkane exposure (from the Catalogue of Somatic Mutational Signatures in Cancer) and firefighting years (<i>p</i> = .04; R² = 0.29). Among nonfirefighters, the individuals with the highest number of median variants attributable to single-base substitution signature 42 also had occupations that possibly exposed them to haloalkanes, such as painting and being a mechanic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In summary, the authors identified gliomas that had mutational signatures associated with haloalkane exposure that were enriched in firefighters and other occupations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35732","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143581593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06)”","authors":"","doi":"10.1002/cncr.35777","DOIUrl":"https://doi.org/10.1002/cncr.35777","url":null,"abstract":"<p>Kim M, Kim YJ, Suh KJ, et al. Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06). <i>Cancer.</i> 2025;131(1):e35609. doi:10.1002/cncr.35609</p><p>In the original title of the article, the Korean Cancer Study Group clinical trial number was incorrectly listed as “UN18-09.” The correct clinical trial number is “UN1806.”</p><p>The authors apologize for this error.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35777","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”","authors":"","doi":"10.1002/cncr.35803","DOIUrl":"https://doi.org/10.1002/cncr.35803","url":null,"abstract":"<p>This erratum corrects the following:</p><p>Luskin MR, Yin J, Lozanski G, et al. Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. <i>Cancer.</i> 2025;131(4):e35750. doi:10.1002/cncr.35750</p><p>The article ’s title was originally published in truncated fashion (“Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study”). The revised full title appears below and should read: “Incorporation of Alemtuzumab into Frontline Therapy of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.” The full title as listed above is correct.</p><p>We apologize for this error.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35803","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remedying Black cancer disparities with clinical research prioritization","authors":"Kimlin Ashing PhD,&nbsp;Nadine Barrett PhD,&nbsp;Kim F. Rhoads MD,&nbsp;Folakemi Odedina PhD,&nbsp;Hayley Thompson PhD,&nbsp;Camille Ragin PhD,&nbsp;Timiya S. Nolan PhD, APRN-CNP,&nbsp;Vanessa B. Sheppard PhD","doi":"10.1002/cncr.35785","DOIUrl":"https://doi.org/10.1002/cncr.35785","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>People of African ancestry are overrepresented among lives lost prematurely and persons unnecessarily afflicted with the highest burden of cancer among nonindigenous Americans. Amid the growing advancements in cancer discoveries and innovations, the persistence of cancer disparities affecting Black/African American populations is particularly disturbing and disappointing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Ashing and colleagues in the Alliance of Black Community Outreach and Engagement Scientific Directors of National Cancer Institute–designated cancer centers discuss the excessive cancer burden in Black populations and propose a Cancer Moonshot–focused framework.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The paper posits for research to remedy cancer disparities, there are three critical areas that require action: (1) examine Black/African American heterogeneity; (2) eradicate policies and practices that are biased toward Black/African American populations and limit access to clinical studies/trials; and (3) embrace community engagement and collaborations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This paper extends a call to action focused on eight critical areas for making significant strides to reduce cancer disparities in Black/African American communities: (1) implementation of policies for inclusion, accountability, and coverage; (2) removal of unnecessary barriers to clinical research participation; (3) introduction of continuing clinical research engagement training; (4) broad deployment of provider communication tools and resources for effective patient communication and referrals; (5) diversification of the scientific and clinical workforce; (6) practice of multisectoral and team science; (7) inclusion of community engagement in science; and (8) development of broad and authentic partnerships with our Black/African American communities. Taken together, these pillars support improved engagement with multistakeholder Black/African American communities to close disparities gaps and achieve health equity and justice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}